Fibrocell acquires rights from UCLA; seeks a lead on adult mesenchymal stem cells from dermal skin cells
This article was originally published in Scrip
Executive Summary
Fibrocell Science, a US regenerative cell therapy firm, has been keeping quite busy since US launch in October 2011 of its autologous aesthetic cell therapy laViv (azficel-T), which is indicated to improve smile lines and uses a patient's own collagen-making skin cells, or fibroblasts. The company is venturing into new areas – the most exciting of which is adult mesenchymal stem cells which are derived from dermal skin cells – and is sponsoring a scientific initiative with top academics to try to secure grant funding that will advance many clinical research programmes.
You may also be interested in...
Patient Group Collaboration In Rare Diseases Offers Model For Cell/Gene Therapy Firms
Companies doing groundbreaking work in cell and gene therapies should look to how rare disease drug developers partnered with patient advocacy groups and disease foundations to advance their shared goals, suggested speakers at the Cell & Gene Exchange conference.
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.